Forbes November 22, 2024
On November 12, 2024, Johnson & Johnson took a bold step by filing a lawsuit against the Health Resources and Services Administration over the 340B Drug Pricing Program. The move came following a public squabble over J&J’s plan to adjust how it addresses the cost discounts for 340B purchases. The program changes designed by J&J and HRSA’s response demonstrate the intricate dynamics at play, which have significant implications for patients, hospitals, and drug manufacturers, and signal the urgent need for change to the administration of the 340B program.
As I recently wrote, the 340B discount program has received its share of criticisms, largely due to the lack of transparency into covered entities who receive the discounts from drug manufacturers. Congress...
Today's Sponsors
Today's Sponsor